DM-IMT - Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respiratory Muscle Training in Patients With Myotonic Dystrophy Type 1 (DM-IMT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04052958 |
Recruitment Status :
Completed
First Posted : August 12, 2019
Last Update Posted : May 2, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Myotonic Dystrophy 1 | Device: IMT - inspiratory muscle training | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 45 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Supportive Care |
Official Title: | DM-IMT - Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respiratory Muscle Training in Patients With Myotonic Dystrophy Type 1 |
Actual Study Start Date : | August 15, 2019 |
Actual Primary Completion Date : | December 31, 2021 |
Actual Study Completion Date : | December 31, 2021 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Group 1: Strength Training
Respiratory muscle strength training
|
Device: IMT - inspiratory muscle training
respiratory strength or indurance training with respiratory therapy device |
Active Comparator: Group 2: Endurance Training
Respiratory muscle endurance training
|
Device: IMT - inspiratory muscle training
respiratory strength or indurance training with respiratory therapy device |
No Intervention: Group 3: Control group
no training of respiratory muscles
|
- Safety of recurrent inspiratory muscle training [ Time Frame: nine months ]Intervention-related (serious) adverse events will be assessed as described in protocoll DM-IMT Version 1.2 (26/June/2019). For example a deterioration of > 15% of the FVC compared to the baseline measurements is defined as AE, as is the development of unusual myalgia of the respiratory muscles for more than 12 hours after the respiratory training. Detailed lists of patients experiencing adverse events or SAEs are reported. The severity of the adverse event is classified as mild, moderate or severe. Relationships of an AE to the training are categorized as unassociated, unlikely to be associated, possibly associated or associated. A separate list will be provided for patients who drop out of the study due to AEs. The frequency of adverse events leading to study termination is also summarized. Safety parameters also include lung function tests (PFT, including FVC, FEV1, MIP, MEP), physical examination, vital signs and clinical laboratory tests as required.
- Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by MIP. [ Time Frame: nine months ]The efficacy of the respiratory training is determined by the results of Maximal inspiratory pressure (MIP).
- Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by MIP. [ Time Frame: nine months ]The efficacy of the respiratory training is determined by the results of Maximal inspiratory pressure (MIP).
- Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by MEP. [ Time Frame: nine months ]The efficacy of the respiratory training is determined by the results of Maximal exspiratory pressure (MEP).
- Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by MEP. [ Time Frame: nine months ]The efficacy of the respiratory training is determined by the results of Maximal exspiratory pressure (MEP).
- Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by FVC. [ Time Frame: nine months ]The efficacy of the respiratory training is determined by the results of Forced Vital capacity (FVC).
- Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by FVC. [ Time Frame: nine months ]The efficacy of the respiratory training is determined by the results of Forced Vital capacity (FVC).
- Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by FEV1. [ Time Frame: nine months ]The efficacy of the respiratory training is determined by the results of Forced Expiratory Volume in 1 second (FEV1).
- Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by FEV1. [ Time Frame: nine months ]The efficacy of the respiratory training is determined by the results of Forced Expiratory Volume in 1 second (FEV1).
- Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by pCO2. [ Time Frame: nine months ]The efficacy of the respiratory training is determined by the results of pCO2 in capillary blood gas analysis.
- Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by pCO2. [ Time Frame: nine months ]The efficacy of the respiratory training is determined by the results of pCO2 in capillary blood gas analysis.
- Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by pO2. [ Time Frame: nine months ]The efficacy of the respiratory training is determined by the results of pO2 in capillary blood gas analysis.
- Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by pO2. [ Time Frame: nine months ]The efficacy of the respiratory training is determined by the results of pO2 in capillary blood gas analysis.
- Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by pH. [ Time Frame: nine months ]The efficacy of the respiratory training is determined by the results of pH in capillary blood gas analysis.
- Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by pH. [ Time Frame: nine months ]The efficacy of the respiratory training is determined by the results of pH in capillary blood gas analysis.
- Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by 6-minute-walk-test. [ Time Frame: nine months ]The efficacy of the respiratory training is determined by the results of 6-minute-walk-test.
- Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training compared to patients without training, measured by DM1-Activ. [ Time Frame: nine months ]Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training will be measured by the result of DM1-ACTIV, a Rasch-built DM activity and participation scale for clinical use.
- Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training compared to patients without training, measured by FDSS. [ Time Frame: nine months ]Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training will be measured by the result of the FDSS - FATIGUE AND DAYTIME SLEEPINESS SCALE, a Rasch-built combined fatigue and daytime sleepiness scale specifically designed for patients with DM1.
- Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training compared to patients without training, measured by the questionnaire Respicheck. [ Time Frame: nine months ]Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training will be measured by the result of the RESPICHECK, a questionnaire on clinical symptoms of respiratory insufficiency.
- Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training compared to patients without training, measured by a physical examination. [ Time Frame: nine months ]Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training will be measured by the result of the physical examination.
- Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training compared to patients without training, using the 6-minute-walk-test. [ Time Frame: nine months ]Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training will be measured by the result of the 6-minute-walk-test.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- the patient is willing and able to provide a signed informed consent form
- the patient is ≥ 18 years old
- the diagnosis of type 1 myotonic dystrophy has been confirmed by molecular genetics
- the patient is able and willing to perform pulmonary function tests (PFT) and blood sampling for capillary blood gas analysis (pO2, pCO2) throughout the study, to keep a diary and to complete questionnaires
Exclusion Criteria:
- the patient requires invasive ventilation (non-invasive ventilation is allowed).
- the patient uses non-invasive ventilation more than 16h/day.
- the patient participates in another clinical study that involves therapy.
- the patient cannot perform pulmonary function tests (PFT).
- the patient is diagnosed with central sleep apnea in polysomnography and not sufficiently treated with NIV ventilation.
- the patient is diagnosed with obstructive sleep apnea and not sufficiently treated with NIV ventilation.
- the patient cannot meet the requirements of the study, according to the investigator.
- the patient is unable to complete a 6-minute walking test

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04052958
Germany | |
Friedrich-Baur-Institute, Dep. of Neurology Klinikum der Universitaet Muenchen Munich, Germany | |
Munich, Bavaria, Germany, 80336 |
Principal Investigator: | Stephan Wenninger, Dr.med. | Neurologist |
Responsible Party: | Prof. Dr. Benedikt Schoser, Neurologist, Senior Physician, LMU Klinikum |
ClinicalTrials.gov Identifier: | NCT04052958 |
Other Study ID Numbers: |
Version 1.2 (26. Juni 2019) |
First Posted: | August 12, 2019 Key Record Dates |
Last Update Posted: | May 2, 2022 |
Last Verified: | April 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Myotonic Dystrophy Muscular Dystrophies Muscular Disorders, Atrophic Muscular Diseases Musculoskeletal Diseases Myotonic Disorders |
Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases Nervous System Diseases Neuromuscular Diseases Genetic Diseases, Inborn |